XML 70 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and License Agreements - Contract Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue $ 94,063 $ 212,315   $ 301,326
AbbVie Ireland Unlimited Company | CD71 Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue     $ 4,000  
Amgen Inc | EGFR Products        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue $ 9,700      
Deferred Revenue Recognition Maturity Year 2025      
Astellas Pharma Inc.        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue $ 17,400      
Deferred Revenue Recognition Maturity Year 2026      
Bristol Myers Squibb        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue $ 41,900      
Deferred Revenue Recognition Maturity Year 2025      
ModernaTX, Inc        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue $ 9,300      
Deferred Revenue Recognition Maturity Year One 2026      
Deferred Revenue Recognition Maturity Year Two 2027      
Regeneron Pharmaceuticals, Inc        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue $ 15,600      
Deferred Revenue Recognition Maturity Year 2026